Kestrel Therapeutics
0 followers
About Kestrel Therapeutics
Kestrel Therapeutics is a clinical-stage biotechnology company focused on developing medicines for patients with KRAS-driven cancers. The company aims to create best-in-class small molecule inhibitors that potently and selectively target KRAS, disrupting oncogenic signaling across multiple tumor types. Kestrel is advancing KST-6051, an oral pan-KRAS inhibitor, into a Phase 1 study in patients with advanced cancers. Based in Watertown, Massachusetts, the organization emphasizes science-driven, patient-focused advancement of targeted therapies for cancer.